LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

Search

Guardant Health Inc

Open

BrancheGesundheitswesen

98.45 1.01

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

96

Max

99.34

Schlüsselkennzahlen

By Trading Economics

Einkommen

16M

-112M

Verkäufe

20M

302M

EPS

-0.45

Gewinnspanne

-37.152

Angestellte

2,490

EBITDA

18M

-101M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+30.88% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

737M

13B

Vorheriger Eröffnungskurs

97.44

Vorheriger Schlusskurs

98.45

Nachrichtenstimmung

By Acuity

50%

50%

162 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Mai 2026, 22:54 UTC

Ergebnisse

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13. Mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13. Mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Mai 2026, 23:17 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13. Mai 2026, 23:16 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13. Mai 2026, 23:15 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13. Mai 2026, 23:14 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13. Mai 2026, 23:02 UTC

Market Talk
Ergebnisse

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13. Mai 2026, 22:59 UTC

Market Talk
Ergebnisse

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13. Mai 2026, 22:24 UTC

Ergebnisse

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Organic Revenue Growth 25%>XRO.AU

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Revenue Growth 47%>XRO.AU

13. Mai 2026, 22:22 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13. Mai 2026, 22:18 UTC

Ergebnisse

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13. Mai 2026, 22:16 UTC

Ergebnisse

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13. Mai 2026, 22:13 UTC

Ergebnisse

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13. Mai 2026, 22:12 UTC

Ergebnisse

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero Did Not Declare a Dividend>XRO.AU

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13. Mai 2026, 22:09 UTC

Ergebnisse

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13. Mai 2026, 22:00 UTC

Ergebnisse

Cisco to Shed Jobs for All-In AI Push -- Update

13. Mai 2026, 21:11 UTC

Ergebnisse

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

30.88% Vorteil

12-Monats-Prognose

Durchschnitt 128.88 USD  30.88%

Hoch 175 USD

Tief 92 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

162 / 346 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat